HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

R A Harrington Selected Research

Eptifibatide (Integrilin)

7/2002Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.
2/2002Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
12/2001Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
7/2001Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
3/2001Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
3/2001Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial.
2/2001Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
12/2000Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators.
9/2000Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
9/2000Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


R A Harrington Research Topics

Disease

25Acute Coronary Syndrome
04/2009 - 01/2000
17Unstable Angina
07/2002 - 01/2000
15Myocardial Infarction
03/2005 - 02/2000
9Hemorrhage
10/2017 - 07/2000
7Infarction (Infarctions)
07/2002 - 03/2000
3Ischemia
03/2005 - 06/2001
3Thrombocytopenia (Thrombopenia)
09/2000 - 07/2000
2Non-ST Elevated Myocardial Infarction
04/2009 - 07/2002
2Cardiovascular Diseases (Cardiovascular Disease)
07/2001 - 08/2000
2Chest Pain (Chest Pains)
09/2000 - 03/2000
1Vascular Diseases (Vascular Disease)
01/2019
1Venous Thromboembolism
10/2017
1ST Elevation Myocardial Infarction
07/2002
1Ischemic Stroke
09/2001
1Transient Ischemic Attack
09/2001
1Stroke (Strokes)
09/2001
1Heart Diseases (Heart Disease)
07/2001
1Coronary Disease (Coronary Heart Disease)
04/2001
1Myocardial Ischemia (Ischemic Heart Diseases)
03/2001
1Reperfusion Injury
01/2001
1Pathologic Constriction (Stenosis)
09/2000
1Shock
09/2000
1Cardiogenic Shock
09/2000
1Atherosclerosis
08/2000
1Disease Progression
07/2000
1Heart Failure
06/2000

Drug/Important Bio-Agent (IBA)

19Eptifibatide (Integrilin)FDA Link
07/2002 - 01/2000
17Platelet Membrane GlycoproteinsIBA
02/2002 - 01/2000
5Glycoproteins (Glycoprotein)IBA
02/2002 - 03/2000
4MB Form Creatine KinaseIBA
02/2004 - 01/2000
4Platelet Membrane Glycoprotein IIbIBA
02/2001 - 01/2000
3paragonIBA
07/2005 - 06/2001
3Heparin (Liquaemin)FDA LinkGeneric
03/2005 - 03/2001
2(2S)- 2- (4- (((3S)- 1- acetimidoyl- 3- pyrrolidinyl)oxy)phenyl)- 3- (7- amidino- 2- naphtyl)propanoic acidIBA
03/2005 - 02/2004
2Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
09/2000 - 03/2000
1AnticoagulantsIBA
10/2017
1betrixabanIBA
10/2017
1Enoxaparin (Lovenox)FDA LinkGeneric
10/2017
1Clopidogrel (Plavix)FDA Link
04/2009
1TicagrelorIBA
04/2009
1Purinergic P2Y Receptor AntagonistsIBA
04/2009
1Factor Xa (Coagulation Factor Xa)IBA
03/2005
1Factor Xa InhibitorsIBA
03/2005
1Creatine Kinase (Creatine Phosphokinase)IBA
02/2004
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
09/2001
1Warfarin (Coumadin)FDA LinkGeneric
09/2001
1Hormones (Hormone)IBA
07/2001
1Trinitrotoluene (TNT)IBA
06/2001
1Troponin T (Troponin T1)IBA
06/2001
1LipidsIBA
04/2001
1Technetium Tc 99m Sestamibi (Cardiolite)FDA LinkGeneric
01/2001
1lotrafibanIBA
08/2000
1Abciximab (ReoPro)FDA Link
07/2000
1Hemoglobins (Hemoglobin)IBA
07/2000
1EnzymesIBA
06/2000
1TroponinIBA
01/2000
1Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
01/2000

Therapy/Procedure

19Therapeutics
07/2002 - 01/2000
7Percutaneous Coronary Intervention
02/2004 - 02/2000
3Coronary Artery Bypass (Coronary Artery Bypass Surgery)
04/2009 - 09/2000
2Secondary Prevention
01/2019 - 08/2000
1Hormone Replacement Therapy (Therapy, Hormone Replacement)
07/2001
1Preoperative Period
09/2000
1Platelet Transfusion (Blood Platelet Transfusions)
07/2000